News >

CDK4/6 Inhibitors Showing Survival Gains in Metastatic HR+ Breast Cancer

Caroline Seymour
Published: Tuesday, Aug 06, 2019

Payal D. Shah, MD, an assistant professor of medicine at Perelman School of Medicine, Hospital of the University of Pennsylvania

Payal D. Shah, MD

There are now 3 FDA-approved CDK4/6 inhibitors from which to choose from for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer, all showing an extension in progression-free survival (PFS) and objective response rates (ORR) in the first- and second-line settings. Now, they are demonstrating improvements in overall survival (OS) in select populations as well.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication